<DOC>
	<DOCNO>NCT00782288</DOCNO>
	<brief_summary>This study measure inflammatory effect digitoxin IL-8 neutrophil count induce sputum stable Cystic Fibrosis ( CF ) patient pharmacokinetics digitoxin serum . Funding Source-FDA OOPD</brief_summary>
	<brief_title>Phase II Study Digitoxin Treat Cystic Fibrosis</brief_title>
	<detailed_description>The study conduct randomize , double blind , placebo-controlled , repeat dose trial evaluate effect 28 day digitoxin IL-8 neutrophil concentration induce sputum subject mild moderate cystic fibrosis lung disease . Twenty-four total patient randomize 3 group 8 subject ( 0.05 mg 0.1 mg digitoxin placebo ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Digitoxin</mesh_term>
	<criteria>Inclusion Criteria Male female 1845 year age Confirmed diagnosis CF base follow criterion : positive sweat chloride &gt; = 60 mEq/liter ( pilocarpine iontophoresis ) and/or genotype two identifiable mutation consistent CF FEV1 &gt; = 40 % predict value screen Weight &gt; 45 kg Screening Visit 1 ( dose ) Clinically stable evidence acute upper low respiratory tract infection current pulmonary exacerbation ( see Appendix II ) treatment pulmonary exacerbation within 14 day prior Screen Visit . Subject may rescreen 14 day complete treatment pulmonary exacerbation , healthy time . Ability perform Spirometry . Ability understand sign write informed consent comply requirement study . Use investigational agent within 4week period prior Screen visit . Use medication antineutrophil antiinflammatory effect know effect inflammatory outcome [ azithromycin , gentamicin , amikacin , colistin , ibuprofen , celecoxib , NSAIDs , prednisone corticosteroid ( systemic inhale ) , Advair , cromolyn ( Intal® ) , montelukast ( Singulair® ) , zafirlukast ( Accolate® ) , zileuton ( Zyflo® ) , immunosuppressive agent within 4 week prior Visit # 1 , Day 1 participation study end ( Visit 6 ) . See NOTE end exclusionary criterion subject oral antibiotic therapy . Use topical nasal steroid product least 2 week prior study drug administration discontinue use nasal cell collection Day 28 . Inability unwillingness stop macrolide antibiotic 4 week prior Day 1 participation study end . Prior use macrolide antibiotic , include maintenance therapy exclude subject participation . History significant cardiac disease cardiac arrhythmia Presence arrhythmia identify screen ECG 24 hour holter monitor Pulmonary hypertension History significant cardiac disease cardiac arrhythmia Presence clinically significant arrhythmia identify screen ECG 24 hour holter monitor . Pulmonary hypertension Burkholderia species sputum within 2 year Screen visit Drugs know interact digitoxin include phenobarbital , amphotericin B , rifampicin , diltiazem , verapamil drug would potentiate potassium loss ( certain diuretic excessive laxative use , define twice daily use miralax ) . Unwillingness use betaagonists ( levalbuterol ) prior induce sputum procedure . Oxygen saturation &lt; 92 % room air Screen visit Pregnant , breastfeeding , unwilling use effective form birth control duration study History significant hemoptysis &gt; = 60cc per episode 30 day prior Screening visit Significant history hepatic , cardiovascular , renal , neurological , hematologic , peptic ulcer disease SGOT ( ALT ) SGPT ( AST ) &gt; 3 time upper limit normal Screen , document biliary cirrhosis , portal hypertension Creatinine &gt; 1.8 mg/dL Screen Inability swallow pill Potassium , serum &lt; 3.3 mEq/L screen Known inability produce sputum ( unable expectorate , must able produce induce sputum sample screen ) . Presence condition abnormality opinion Investigator would compromise safety subject quality data NOTE : For subject continuous antibiotic therapy least 6 month one continuous antibiotic alternate two different antibiotic , maintain current therapy . If subject alternate two different inhale antibiotic month , Visit 1 coincide `` '' cycle one inhale antibiotic consistency treatment period . For subject alternate month TOBI® , colistin Cayston therapy , `` '' cycle must coincide Treatment Phase study . Subjects schedule Screening Visit onemonth `` '' period , may resume take TOBI® , colistin Cayston completion Visit 6 ( Day 42 ) early termination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>digitoxin</keyword>
	<keyword>inflammatory marker</keyword>
	<keyword>cytokine</keyword>
	<keyword>gene expression</keyword>
</DOC>